These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 26957110)
1. GS-9857 in patients with chronic hepatitis C virus genotype 1-4 infection: a randomized, double-blind, dose-ranging phase 1 study. Rodriguez-Torres M; Glass S; Hill J; Freilich B; Hassman D; Di Bisceglie AM; Taylor JG; Kirby BJ; Dvory-Sobol H; Yang JC; An D; Stamm LM; Brainard DM; Kim S; Krefetz D; Smith W; Marbury T; Lawitz E J Viral Hepat; 2016 Aug; 23(8):614-22. PubMed ID: 26957110 [TBL] [Abstract][Full Text] [Related]
2. Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics. Lawitz E; Sulkowski M; Jacobson I; Kraft WK; Maliakkal B; Al-Ibrahim M; Gordon SC; Kwo P; Rockstroh JK; Panorchan P; Miller M; Caro L; Barnard R; Hwang PM; Gress J; Quirk E; Mobashery N Antiviral Res; 2013 Sep; 99(3):214-20. PubMed ID: 23747481 [TBL] [Abstract][Full Text] [Related]
3. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients. Reesink HW; Fanning GC; Farha KA; Weegink C; Van Vliet A; Van 't Klooster G; Lenz O; Aharchi F; Mariën K; Van Remoortere P; de Kock H; Broeckaert F; Meyvisch P; Van Beirendonck E; Simmen K; Verloes R Gastroenterology; 2010 Mar; 138(3):913-21. PubMed ID: 19852962 [TBL] [Abstract][Full Text] [Related]
4. A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C. Lawitz EJ; Gruener D; Hill JM; Marbury T; Moorehead L; Mathias A; Cheng G; Link JO; Wong KA; Mo H; McHutchison JG; Brainard DM J Hepatol; 2012 Jul; 57(1):24-31. PubMed ID: 22314425 [TBL] [Abstract][Full Text] [Related]
5. Rapid decline of viral RNA in chronic hepatitis C patients treated once daily with IDX320: a novel macrocyclic HCV protease inhibitor. de Bruijne J; van Vliet A; Weegink CJ; Mazur W; Wiercinska-Drapało A; Simon K; Cholewińska-Szymańska G; Kapocsi J; Várkonyi I; Zhou XJ; Temam MF; Molles J; Chen J; Pietropaolo K; McCarville JF; Sullivan-Bólyai JZ; Mayers D; Reesink H Antivir Ther; 2012; 17(4):633-42. PubMed ID: 22427481 [TBL] [Abstract][Full Text] [Related]
6. Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study. Forestier N; Larrey D; Guyader D; Marcellin P; Rouzier R; Patat A; Smith P; Bradford W; Porter S; Blatt L; Seiwert SD; Zeuzem S J Hepatol; 2011 Jun; 54(6):1130-6. PubMed ID: 21145848 [TBL] [Abstract][Full Text] [Related]
7. A Phase I, randomized, placebo-controlled, 3-day, ascending-dose study of GS-9451, an NS3/4A protease inhibitor, in genotype 1 hepatitis C patients. Lawitz EJ; Hill JM; Marbury T; Demicco MP; Delaney W; Yang J; Moorehead L; Mathias A; Mo H; McHutchison JG; Rodriguez-Torres M; Gordon SC Antivir Ther; 2013; 18(3):311-9. PubMed ID: 23047118 [TBL] [Abstract][Full Text] [Related]
8. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Gane EJ; Roberts SK; Stedman CA; Angus PW; Ritchie B; Elston R; Ipe D; Morcos PN; Baher L; Najera I; Chu T; Lopatin U; Berrey MM; Bradford W; Laughlin M; Shulman NS; Smith PF Lancet; 2010 Oct; 376(9751):1467-75. PubMed ID: 20951424 [TBL] [Abstract][Full Text] [Related]
9. A phase 1, randomized, dose-ranging study of GS-5816, a once-daily NS5A inhibitor, in patients with genotype 1-4 hepatitis C virus. Lawitz E; Freilich B; Link J; German P; Mo H; Han L; Brainard DM; McNally J; Marbury T; Rodriguez-Torres M J Viral Hepat; 2015 Dec; 22(12):1011-9. PubMed ID: 26183611 [TBL] [Abstract][Full Text] [Related]
10. A randomized, double blind, dose escalation, first time in human study to assess the safety, tolerability, pharmacokinetics, and antiviral activity of single doses of GSK2485852 in chronically infected hepatitis C subjects. Wilfret DA; Walker J; Voitenleitner C; Baptiste-Brown S; Lovern M; Kim J; Adkison K; Shotwell B; Mathis A; Moss L; Lee D; Yu L; Gan J; Spaltenstein A Clin Pharmacol Drug Dev; 2014 Nov; 3(6):439-48. PubMed ID: 27129119 [TBL] [Abstract][Full Text] [Related]
11. Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection. Lawitz EJ; O'Riordan WD; Asatryan A; Freilich BL; Box TD; Overcash JS; Lovell S; Ng TI; Liu W; Campbell A; Lin CW; Yao B; Kort J Antimicrob Agents Chemother; 2015 Dec; 60(3):1546-55. PubMed ID: 26711747 [TBL] [Abstract][Full Text] [Related]
12. Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Reiser M; Hinrichsen H; Benhamou Y; Reesink HW; Wedemeyer H; Avendano C; Riba N; Yong CL; Nehmiz G; Steinmann GG Hepatology; 2005 Apr; 41(4):832-5. PubMed ID: 15732092 [TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind, multiple-dose study of the pan-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4. Vince B; Hill JM; Lawitz EJ; O'Riordan W; Webster LR; Gruener DM; Mofsen RS; Murillo A; Donovan E; Chen J; McCarville JF; Sullivan-Bólyai JZ; Mayers D; Zhou XJ J Hepatol; 2014 May; 60(5):920-7. PubMed ID: 24434503 [TBL] [Abstract][Full Text] [Related]
14. All-oral therapy with nucleotide inhibitors sofosbuvir and GS-0938 for 14 days in treatment-naive genotype 1 hepatitis C (nuclear). Lawitz EJ; Rodriguez-Torres M; Denning J; Mathias A; Mo H; Gao B; Cornpropst MT; Berrey MM; Symonds WT J Viral Hepat; 2013 Oct; 20(10):699-707. PubMed ID: 24010644 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naïve or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 Infections. Gane EJ; Schwabe C; Hyland RH; Yang Y; Svarovskaia E; Stamm LM; Brainard DM; McHutchison JG; Stedman CA Gastroenterology; 2016 Sep; 151(3):448-456.e1. PubMed ID: 27240903 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics, pharmacodynamics, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor, following multiple ascending doses in patients with chronic hepatitis C infection. Lawitz E; Rodriguez-Torres M; Denning JM; Albanis E; Cornpropst M; Berrey MM; Symonds WT Antimicrob Agents Chemother; 2013 Mar; 57(3):1209-17. PubMed ID: 23263000 [TBL] [Abstract][Full Text] [Related]
17. Safety, pharmacokinetics and pharmacodynamics of the oral toll-like receptor 7 agonist GS-9620 in treatment-naive patients with chronic hepatitis C. Lawitz E; Gruener D; Marbury T; Hill J; Webster L; Hassman D; Nguyen AH; Pflanz S; Mogalian E; Gaggar A; Massetto B; Subramanian GM; McHutchison JG; Jacobson IM; Freilich B; Rodriguez-Torres M Antivir Ther; 2015; 20(7):699-708. PubMed ID: 25105516 [TBL] [Abstract][Full Text] [Related]
18. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Manns M; Pol S; Jacobson IM; Marcellin P; Gordon SC; Peng CY; Chang TT; Everson GT; Heo J; Gerken G; Yoffe B; Towner WJ; Bourliere M; Metivier S; Chu CJ; Sievert W; Bronowicki JP; Thabut D; Lee YJ; Kao JH; McPhee F; Kopit J; Mendez P; Linaberry M; Hughes E; Noviello S; Lancet; 2014 Nov; 384(9954):1597-605. PubMed ID: 25078304 [TBL] [Abstract][Full Text] [Related]
19. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Jacobson IM; Dore GJ; Foster GR; Fried MW; Radu M; Rafalsky VV; Moroz L; Craxi A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Scott J; Sinha R; Beumont-Mauviel M Lancet; 2014 Aug; 384(9941):403-13. PubMed ID: 24907225 [TBL] [Abstract][Full Text] [Related]